Deal filing: BMS added CVR late in Celgene negotiations

Celgene Corp. (NASDAQ:CELG) rejected multiple overtures from Bristol-Myers Squibb Co. (NYSE:BMY) and solicited a bid from another pharma before accepting BMS's takeout offer last month -- but not before BMS replaced some guaranteed money with a contingent value right late in the negotiations.

Following discussions that began almost two years prior, the companies formally consummated their deal early Jan. 3, with

Read the full 605 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE